Curanex Pharmaceuticals Inc (CURX) Income Statement
CURX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsCURX revenue and net income
CURX profit margins
CURX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
CURX quarterly EPS vs estimates
Curanex Pharmaceuticals beat the analyst EPS estimate in 0 of the last 1 quarters. Next report: November 13, 2026.
CURX income statement
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $26,000 |
| Cost of revenue | — | — | $0 | $21,571 |
| Gross profit | — | — | $0 | $4,429 |
| Research & development | $3.0M | $0 | — | — |
| Sales, general & admin | $1.3M | $290,386 | $19,298 | $24,662 |
| Total operating expenses | $4.2M | $365,062 | $19,298 | $24,662 |
| Operating income | −$4.2M | −$365,062 | −$19,298 | −$20,233 |
| Interest expense | $8,537 | $0 | — | — |
| Income before taxes | −$4.2M | −$361,506 | −$19,198 | −$20,233 |
| Net income | −$4.2M | −$361,506 | −$19,198 | −$20,233 |
| EBITDA | −$4.1M | −$290,386 | −$17,483 | $925 |
| EPS (diluted) | −$2.22 | −$0.26 | −$0.01 | — |
| Gross margin | — | — | — | 17.0% |
| Operating margin | — | — | — | −77.8% |
| Net margin | — | — | — | −77.8% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $35,041 | $34,294 | — | $15,030 | — | — | — | — | — | — |
| Gross profit | — | −$35,041 | −$34,294 | — | −$15,030 | — | — | — | — | — | — |
| Research & development | $2.6M | $2.3M | $2.3M | $677,474 | $0 | $0 | — | $0 | — | — | — |
| Sales, general & admin | $731,843 | $927,197 | $784,240 | $273,853 | $57,658 | $137,452 | $63,915 | $102,070 | $44,200 | — | — |
| Total operating expenses | $3.3M | $3.1M | $3.1M | $951,327 | $57,658 | $137,452 | $138,591 | $102,070 | $44,200 | $80,201 | $12,671 |
| Operating income | −$3.3M | −$3.2M | −$3.1M | −$951,327 | −$57,658 | −$137,452 | −$138,591 | −$102,070 | −$44,200 | −$80,201 | −$12,671 |
| Interest expense | $0 | $0 | $17,074 | $4,090 | $3,091 | $1,356 | — | $0 | $0 | — | — |
| Income before taxes | −$3.3M | −$3.2M | −$3.1M | −$954,059 | −$60,346 | −$137,583 | −$137,163 | −$99,942 | −$44,200 | −$80,201 | −$12,671 |
| Net income | −$3.3M | −$3.2M | −$3.1M | −$954,059 | −$60,346 | −$137,583 | −$137,163 | −$99,942 | −$44,200 | −$80,201 | −$12,671 |
| EBITDA | −$3.3M | −$3.1M | −$3.1M | −$934,530 | −$42,225 | −$121,594 | −$63,915 | −$102,070 | −$44,200 | −$80,201 | −$12,671 |
| EPS (diluted) | −$0.03 | −$2.22 | −$2.17 | −$0.04 | −$0.01 | — | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in CURX's financial statements (latest annual report filed March 30, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
CURX financial results
Curanex Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $4.2 million. Diluted earnings per share came to −$2.22.
See the CURX stock overview for the latest quote and news, or the CURX chart for price history and technical indicators.
CURX income statement FAQ
Does Curanex Pharmaceuticals have revenue?
Curanex Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Curanex Pharmaceuticals profitable?
No. Curanex Pharmaceuticals reported a net loss of $4.2 million in fiscal 2025.
How much does Curanex Pharmaceuticals spend on research and development?
Curanex Pharmaceuticals spent $3.0 million on research and development in fiscal 2025.
What are Curanex Pharmaceuticals's earnings per share?
Curanex Pharmaceuticals earned $-2.22 per diluted share in fiscal 2025, compared with $-0.26 a year earlier.
When will Curanex Pharmaceuticals report its next earnings?
Curanex Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026.
When does Curanex Pharmaceuticals's fiscal year end?
Curanex Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 30, 2026.